Loading Events
EORTC Lung Cancer Group

EORTC Lung Cancer Group Virtual meeting

Virtual Event

The EORTC Lung Cancer Group Virtual meeting will be held from 13:00 to 17:00 CET.

 

Time slot Topic / Title of presentation

Speaker

12:00 – 12:45 LCG board meeting
13.00 – 13.15 Introduction B. Besse
13:15 – 13:25 LCG Treasurer and Secretary (mandates 2021 – 2024) Call for trials on new drugs A. Dingemans
13:25 – 13:35 Status update on recruiting protocols: 1205 and 08112 (NEMO), 1525 (Nivothym), 1702 (HALT), 1825 (ALKALINE) A. Pochesci
13:35 – 13:45 Status update on protocols with recruitment target reached: 1416 (PEARLS), 1417 (REACTION), 1613 (APPLE) A. Pochesci
 

13:45 – 14:00

Protocol in development in SCLC

1901 (PRIMAlung): PRophylactic cerebral Irradiation or active MAgnetic resonance imaging surveillance in small-cell Lung cancer patients (PRIMALung study).

 

A. Levy

New study proposals

  • Phase III open-label randomized study of pembrolizumab plus carboplatin and pemetrexed vs chemotherapy alone in advanced PD-L1 ≥1% non- squamous non-small cell lung cancer patients progressing on first-line PD-1/PD-L1 inhibition
 

 

L. Toschi

14:00 – 15:00
  • NEOTIKI: NEOadjuvant TIrosine Kinase Inhibitors in oncogenic-addicted early stage NSCLC patients
J. Remon
  • RANCIM: RAndomized trial of Chemotherapy w/wo

Neoadjuvant Checkpoint Inhibitor in resectable malignant pleural Mesothelioma

J. Van Meerbeeck, J. Raskin, P. Van Schil & L. Lang-Lazdunski
15:00 – 15:10 Break
Ongoing proposals
  • Platinum-based CMT + ICI +/- bevacizumab in
15:10 – 15:25 advanced non-squamous NSCLC patients with untreated/progressing brain metastases E. Dudnik
  • Randomized phase III study of first line immunotherapy
15:25 – 15:40 versus immunotherapy plus platinum-doublet chemotherapy in PD-L1 TPS ≥ 50% metastatic NSCLC L. Hendriks
patients
 

15:45 – 16:00

  • Immunotherapy Consolidation After Radical treatment of Synchronous Oligo-metastatic NSCLC: ICARS
F. Aboubakar
 

16:00 – 16:15

  • Randomized phase II trial of osimertinib compared to osimertinib plus local ablative therapy (LAT) in the

treatment of oligoresidual EGR positive NSCLC

 

M. Giaj Levra

(RALATO study)
 

16:40 – 17:00

Young Investigators Projects

  • Summary of activities
  • AI questionnaire
  • ECHO study
 

M. Giaj Levra, J. Menis
J. Menis
J. Menis

17:00 – 17:30 Virtual cocktail